Zhigang C Wang

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations
    Nicolai Juul Birkbak
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark
    PLoS ONE 8:e80023. 2013
  2. ncbi request reprint Molecular characterization of the HLA-Cw*0409N allele
    Zhigang C Wang
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Hum Immunol 63:295-300. 2002
  3. ncbi request reprint Maternal CD46H*2 and IL1B-511*1 homozygosity in T helper 1-type immunity to trophoblast antigens in recurrent pregnancy loss
    Zhigang C Wang
    Fearing Laboratory, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Hum Reprod 21:818-22. 2006
  4. pmc Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
    Daniel P Silver
    Dana Farber Cancer Institute, Department of Medical Oncology, Smith 209, 1 Jimmy Fund Way, Boston, MA 02115, USA
    J Clin Oncol 28:1145-53. 2010
  5. ncbi request reprint X chromosomal abnormalities in basal-like human breast cancer
    Andrea L Richardson
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 9:121-32. 2006
  6. pmc SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis
    Hailing Cheng
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Sci Signal 2:ra35. 2009
  7. pmc Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents
    Nicolai J Birkbak
    Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark
    Cancer Discov 2:366-75. 2012
  8. doi request reprint Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome
    Zhigang C Wang
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:5806-15. 2012
  9. pmc Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
    Nadine Tung
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Breast Cancer Res 12:R95. 2010
  10. pmc The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis
    Tamara Utermark
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Genes Dev 26:1573-86. 2012

Collaborators

Detail Information

Publications16

  1. pmc Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations
    Nicolai Juul Birkbak
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark
    PLoS ONE 8:e80023. 2013
    ..The significance of these genome-wide mutations is unknown. We hypothesize genome-wide mutation burden mirrors deficiencies in DNA repair and is associated with treatment outcome in ovarian cancer...
  2. ncbi request reprint Molecular characterization of the HLA-Cw*0409N allele
    Zhigang C Wang
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Hum Immunol 63:295-300. 2002
    ..These results indicate that the HLA-Cw*0409N allele may produce a putative long HLA-Cw4 heavy chain that is not expressed on the cell surface...
  3. ncbi request reprint Maternal CD46H*2 and IL1B-511*1 homozygosity in T helper 1-type immunity to trophoblast antigens in recurrent pregnancy loss
    Zhigang C Wang
    Fearing Laboratory, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Hum Reprod 21:818-22. 2006
    ....
  4. pmc Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
    Daniel P Silver
    Dana Farber Cancer Institute, Department of Medical Oncology, Smith 209, 1 Jimmy Fund Way, Boston, MA 02115, USA
    J Clin Oncol 28:1145-53. 2010
    ..CONCLUSION Single-agent cisplatin induced response in a subset of patients with TNBC. Decreased BRCA1 expression may identify subsets of TNBCs that are cisplatin sensitive. Other biomarkers show promise in predicting cisplatin response...
  5. ncbi request reprint X chromosomal abnormalities in basal-like human breast cancer
    Andrea L Richardson
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 9:121-32. 2006
    ..Other, equally aneuploid, but non-BLC rarely displayed these X chromosome abnormalities. These results suggest that X chromosome abnormalities contribute to the pathogenesis of BLC, both inherited and sporadic...
  6. pmc SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis
    Hailing Cheng
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Sci Signal 2:ra35. 2009
    ..Together, these findings indicate that SIK1 links LKB1 to p53-dependent anoikis and suppresses metastasis...
  7. pmc Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents
    Nicolai J Birkbak
    Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark
    Cancer Discov 2:366-75. 2012
    ..Thus, accumulation of telomeric allelic imbalance is a marker of platinum sensitivity and suggests impaired DNA repair...
  8. doi request reprint Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome
    Zhigang C Wang
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:5806-15. 2012
    ..Defective HRR causes uniparental deletions and loss of heterozygosity (LOH). Our purpose is to profile LOH in HGSC and correlate our findings to clinical outcome, and compare HGSC and high-grade breast cancers...
  9. pmc Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
    Nadine Tung
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Breast Cancer Res 12:R95. 2010
    ....
  10. pmc The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis
    Tamara Utermark
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Genes Dev 26:1573-86. 2012
    ..Our findings demonstrate a novel p110β-based regulatory role in receptor-mediated PI3K activity and identify p110α as an important target for treatment of HER2-positive disease...
  11. pmc Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling
    Christina Gewinner
    Division of Signal Transduction, Beth Israel Deaconess Medical Center, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 16:115-25. 2009
    ....
  12. ncbi request reprint Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers
    Zhigang C Wang
    Departments of Surgery and Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Res 64:64-71. 2004
    ..Furthermore, exclusive association between biological subclasses and restricted LOH events provides rationale to search for targeted genes...
  13. ncbi request reprint A role for the scaffolding adapter GAB2 in breast cancer
    Mohamed Bentires-Alj
    Cancer Biology Program, Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, NRB 1030, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA
    Nat Med 12:114-21. 2006
    ..Agents that target GAB2 or GAB2-dependent pathways may be useful for treating breast tumors that overexpress GAB2 or HER2 or both...
  14. ncbi request reprint BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles
    Evan Matros
    Department of Surgery, Brigham and Women s Hospital, Boston, MA 02115, USA
    Breast Cancer Res Treat 91:179-86. 2005
    ..Absence of BRCA1 promoter methylation and high levels of BRCA1 expression in basal-like sporadic tumors suggest alternate explanations for the phenotypic similarities of these tumors to hereditary BRCA1 tumors...
  15. ncbi request reprint Genomic approaches in cancer biology
    Evan Matros
    Department of Surgery and Pathology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, Mass, USA
    Surgery 136:511-8. 2004
  16. doi request reprint Predicting features of breast cancer with gene expression patterns
    Xuesong Lu
    Bioinformatics Division, TNLIST and Department of Automation, Tsinghua University, Beijing 100084, China
    Breast Cancer Res Treat 108:191-201. 2008
    ..Results are consistent with a model of regional metastasis that depends on inherent biologic differences in metastatic propensity between breast cancer subtypes, upon which time and chance then operate...